补肺定喘方联合吉非替尼治疗晚期肺腺癌临床研究

Clinical Study of Bufeidingchuan Prescription Combined Gefitinib Treatment of Advanced Lung Cancer

目的观察补肺定喘方联合吉非替尼治疗晚期肺腺癌临床疗效和不良反应。方法 76例晚期肺腺癌随机分为治疗组和对照组,各38例,治疗组采用补肺定喘方联合吉非替尼方案,对照组采用口服吉非替尼方案,30d为一周期。结果治疗组有效率为42.11%,对照组为39.47%,两组比较无明显统计学意义(P>0.05);皮疹发生率、胃肠道反应治疗组均明显低于对照组,两组有明显统计学意义(P<0.05);治疗组在细胞免疫功能均显著高于对照组,两组比较有明显统计学意义(P<0.05)。结论补肺定喘方联合吉非替尼治疗晚期肺腺癌疗效确切,明显减轻不良反应,增强免疫功能,提高患者生存质量,延长生存期。

Objective To observe the Bufeidingchuan prescription combined gefitinib treatment of advanced lung cancer clinical efficacy and toxicity reactions. Methods 76 patients with advanced lung cancer were randomly divided into treatment group and control group, the 38 cases, the treatment group were combined Bufeidingchuan side of gefitinib in the control group with oral gefitinib program, 30 days as one cycle. Results The treatment group was 42.11%, 39.47% in control group showed no statistically significant （P〉0.05）; rash incidence of gastrointestinal side effects of treatment group was significantly lower than control group significantly statistically significant （P〈0.05）; cellular immune function in the treatment group were significantly higher in the two groups are statistically significant （P〈0.05）. Conclusion Bufeidingchuan prescription combined with gefitinib is effective in treatment of advanced lung cancer, significantly reduced toxicity, enhanced immune function, improve patient quality of life and prolong survival.